文献速递前列腺癌

根治性前列腺切除术后淋巴结阳性前列腺癌患者立即放疗与观察的比较

Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-11-25

本研究利用美国国家癌症数据库2006至2015年数据,模拟辅助放疗对比观察治疗pN1前列腺癌的假想试验,纳入3510例患者,其中587例(17%)接受辅助放疗。经重加权后,辅助放疗与观察的5年总生存率为93%对89%,7年为82%对79%(p=0.11),辅助放疗与全因死亡风险降低相关但未达统计学显著(HR 0.70,p=0.06)。仅在Gleason评分8-10、≥2枚阳性淋巴结或手术切缘阴性亚组中,辅助放疗与总生存改善相关。

要点

  • 在pN1前列腺癌中,辅助放疗与观察相比,全因死亡风险降低但未达统计学显著(HR 0.70,p=0.06)。
  • 辅助放疗与观察的5年总生存率为93%对89%,7年为82%对79%(p=0.11)。
  • 仅Gleason 8-10、≥2枚阳性淋巴结或切缘阴性者中,辅助放疗与总生存改善相关。

核心结论

  • 在模拟辅助放疗对比观察的观察性分析中,辅助放疗仅与Gleason 8-10、≥2枚阳性淋巴结或手术切缘阴性男性的总生存改善相关。

研究设计与样本

  • 利用美国国家癌症数据库2006至2015年数据,模拟以RADICALS-RT试验设计为依据的假想试验,纳入50-69岁、pT2-3 Rany pN1 M0、治疗前PSA<50 ng/mL、接受根治性前列腺切除术后26周内60-72 Gy辅助放疗±雄激素剥夺治疗或观察的男性。
  • 共纳入3510例患者,其中587例(17%)接受辅助放疗(73%同步雄激素剥夺治疗)。
  • 采用倾向性评分和稳定逆概率治疗加权(sIPW)估计绝对和相对治疗效果。

主要发现

  • 中位随访40.0个月,期间发生333例死亡。
  • sIPW重加权后基线特征均衡;辅助放疗对比观察的5年总生存率为93%对89%,7年为82%对79%(p=0.11)。
  • 逆概率加权Cox回归中,辅助放疗与观察相比全因死亡风险降低但未达统计学显著(HR 0.70,p=0.06)。
  • 亚组分析中,辅助放疗仅与Gleason 8-10疾病(HR 0.59,p=0.01)、≥2枚阳性淋巴结(2枚阳性淋巴结HR 0.49,p=0.04;≥3枚阳性淋巴结HR 0.42,p=0.01)或手术切缘阴性(HR 0.50,p=0.02)男性的全因死亡改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal management of node-positive (pN1) prostate cancer following radical prostatectomy (RP) remains uncertain. Despite randomized evidence, utilization of immediate, life-long androgen deprivation therapy (ADT) remains poor, and recent trials of early salvage radiotherapy included only a minority of pN1 patients. We therefore emulated a hypothetical pragmatic trial of adjuvant radiotherapy versus observation in men with pN1 prostate cancer. METHODS: Using the RADICALS-RT trial to inform the design of a hypothetical trial, we identified men aged 50-69 years with pT2-3 Rany pN1 M0, pre-treatment PSA < 50 ng/mL prostate cancer in the NCDB from 2006 to 2015 treated with 60-72 Gy of adjuvant RT (aRT) ± ADT within 26 weeks of RP or observation. After estimating a propensity score for receipt of aRT, we estimated absolute and relative treatment effects using stabilized inverse probability of treatment (sIPW) re-weighting. RESULTS: In total, 3510 patients were included in the study, of whom 587 (17%) received aRT (73% with concurrent ADT). Median follow-up was 40.0 -months, during which 333 deaths occurred. After sIPW re-weighting, baseline characteristics were well-balanced. Adjusted overall survival (OS) was 93% versus 89% at 5-years and 82% versus 79% at 7-years for aRT versus observation (p = 0.11). In IPW-reweighted Cox regression, aRT was associated with a lower risk of all-cause mortality (ACM) than observation, but this did not reach statistical significance (HR 0.70 p = 0.06). In analyses examining heterogeneity of treatment effects, aRT was associated with improved ACM only for men with Gleason 8-10 disease (HR 0.59, p = 0.01), ≥2 positive LNs (HR 0.49, p = 0.04 for 2 positive LNs; HR 0.42, p = 0.01 for ≥3 positive LNs), or negative surgical margins (HR 0.50, p = 0.02). CONCLUSIONS: In observational analyses designed to emulate a hypothetical target trial of aRT versus observation in pN1 prostate cancer, aRT was associated with improved OS only for men with Gleason 8-10 disease, ≥2 positive LNs, or negative surgical margins.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Schaufler C, Kaul S, Fleishman A, et al. Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis. 2022. PMID: 36434164. doi:10.1038/s41391-022-00619-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。